Healthcare Voaltile Stocks: Zogenix, Inc. (NASDAQ:ZGNX), IsoRay, Inc. (NYSEMKT:ISR), Avanir Pharmaceuticals (NASDAQ:AVNR), Insmed Incorporated (NASDAQ:INSM)

Zogenix, Inc.’s (NASDAQ:ZGNX ) shares soared 20.51% after the company announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER (opioid agonist, extended-release, oral formulation of hydrocodone bitartrate) on Constitutional grounds. Zogenix, Inc. (NASDAQ:ZGNX) shares after opening at $2.83 moved to $2.94 on last trade day and at the end of the day closed at $2.71. Company price to sales ratio in past twelve months was calculated as 11.46 and price to cash ratio as 5.25. Zogenix, Inc. (NASDAQ:ZGNX) showed a positive weekly performance of 5.86%.

Trade-Ideas LLC identified IsoRay, Inc. (NYSEMKT:ISR) as a “perilous reversal”  candidate. In addition to specific proprietary factors, Trade-Ideas identified IsoRay as such a stock due to the following factors. ISR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $37.4 million. IsoRay, Inc. (NYSEMKT:ISR) shares advanced 0.42% in last trading session and ended the day on $2.40. ISR return on equity ratio is recorded as -71.90% and its return on assets is -56.60%. IsoRay, Inc. (NYSEMKT:ISR) yearly performance is 370.59%.

Avanir Pharmaceuticals (NASDAQ:AVNR) saw a significant decline in short interest in the month of January. As of March 14th, there was short interest totalling 15,856,677 shares, a decline of 6.5% from the February 28th total of 16,951,290 shares, Analyst Ratings.Net reports. Based on an average daily trading volume, of 3,007,264 shares, the days-to-cover ratio is presently 5.3 days. Currently, 10.6% of the company’s shares are sold short.Avanir Pharmaceuticals Inc (NASDAQ:AVNR) shares moved up 1.17% in last trading session and was closed at $3.40, while trading in range of $ 3.34 – 3.63. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) year to date (YTD) performance is 2.98%.

Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company focused on patients suffering with lung diseases through the development and commercialization of targeted inhalation therapies. The Company’s lead candidate ARIKACE, is engineered to deliver anti-infective directly to the site of lung infections for at least two identified patient populations: cystic fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections and patients with nontuberculous mycobacteria lung infections (NTM). Insmed Incorporated (NASDAQ:INSM) weekly performance is -14.04%. On last trading day company shares ended up $13.41. Insmed Incorporated (NASDAQ:INSM) distance from 50-day simple moving average (SMA50) is -25.21%. Analysts mean target price for the company is $28.29.